The therapeutic response of feline mammary fibroepithelial hyperplasia to aglepristone: A case report
Article Sidebar
Main Article Content
Abstract
Feline Mammary Fibroepithelial Hyperplasia (FMFH) is a non-neoplastic condition most commonly found in intact female cats, particularly after ovulation or following exposure to exogenous progesterone. The pathogenesis involves the stimulation of progesterone receptors in mammary epithelial and stromal cells, together with the influence of local growth factors such as IGF-1 and EGF. This combined effect leads to rapid cellular proliferation and inhibition of apoptosis. This case report describes an intact female cat diagnosed with FMFH following weaning. The cat was treated with aglepristone (AlizinTM, Virbac, Bangkok), a progesterone receptor antagonist, administered subcutaneously at a dose of 10 mg/kg on days 1, 2, 3, 4, and 9. The mammary glands gradually decreased in size within 7–10 days, with clinical improvement. Adjunctive therapies, including anti-microbial, anti-inflammatory drugs, and topical cool compresses, were also implemented to manage local inflammation. These findings support the use of aglepristone as an effective treatment for FMFH in cats, particularly when ovariohysterectomy (OVH) is not immediately feasible for the owners. Nevertheless, to prevent recurrence, OVH is recommended once the condition has resolved, as progesterone remains the primary trigger for disease reactivation during subsequent estrous cycles.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Concannon, P.W. (2011). Physiology of reproduction and hormonal treatments in cats. Reproduction in Domestic Animals, 46(Suppl 6), 160–163.
Fontaine, E., Fontbonne, A., and Carré, S. (2006). Mammary fibroadenomatous hyperplasia in the queen: A clinical approach. Journal of Feline Medicine and Surgery, 8(5), 291–299.
González-González, R., Sánchez-Montes, S., and Martínez-Burgos, M. (2012). Mammary gland development and lactation in the cat. Theriogenology, 78(1), 18–26.
Görlinger, S., Kooistra, H.S., van den Broek, A., and Okkens, A.C. (2002). Treatment of fibroadenomatous hyperplasia in cats with aglépristone. Journal of Veterinary Internal Medicine, 16(6), 710–713.
Gudermuth, D.F., Newton, L., Daels, P., and Concannon, P. W. (1997). Spontaneous ovulation in cats. Theriogenology, 47(7), 1413–1421.
Johnson, A.K. (2022). Normal feline reproduction: The queen. Journal of Feline Medicine and Surgery, 24(3), 204–211
Köhler, K., Schweikle, T., Müller, E., Kramer, M., and Thalhammer, J.G. (2010). Treatment of feline mammary fibroepithelial hyperplasia with the progesterone antagonist aglepristone. Journal of Feline Medicine and Surgery, 12(6), 434–438.
Loretti, A. P., Ilha, M. R. S., Orness, M., and Driemeier, D. (2004). Clinical, pathological and immunohistochemical aspects of feline mammary fibroadenomatous change. Veterinary Pathology, 41(2), 181–183.
Loretti, A.P., and Ilha, M.R.S. (2019). Mammary fibroadenomatous hyperplasia in cats: Pathologic features and diagnostic considerations. Veterinary Pathology, 56(3), 389–397.
Marino, G., Zanzani, S. A., and Roccabianca, P. (2021). Conservative management of feline mammary fibroadenomatous hyperplasia: A review of current evidence. Animals, 11(4), 1123.
Mathews, K., Kronen, P.W., Lascelles, B.D.X., Nolan, A., Robertson, S.A., Steagall, P.V.M., and Yamashita, K. (2014). Guidelines for recognition, assessment and treatment of pain: WSAVA Global Pain Council members and co-authors of this document. Journal of Small Animal Practice, 55(6), E10–E68.
Mills, R.L., Taylor, S.M., and McClure, J.T. (2019). Disorders of the mammary gland in cats. Journal of Feline Medicine and Surgery, 21(8), 760–774.
Munson, L., and Moresco, A. (2025). Feline mammary tumors: A comprehensive review of histological classification schemes, grading systems, and prognostic factors. Veterinary Sciences, 12(8), 736.
Pelican, K.M., Wildt, D.E., and Platz, C.C. (2006). Spontaneous and induced ovulation in the domestic cat. Theriogenology, 66(5), 1342–1346.
Verstegen, J., Onclin, K., and Silva, L.D.M. (1999). Progestins and mammary gland pathology in the dog and the cat. Human Reproduction Update, 5(4), 293–301.
Verstegen, J., and Onclin, K. (2006). Treatment of mammary fibroadenomatous hyperplasia in the cat with aglepristone. Reproduction in Domestic Animals, 41(2), 178–180.
Verstegen, J., Onclin, K., and Silva, L.D.M. (2008). Mammary fibroadenomatous hyperplasia in the cat: Pathophysiology and treatment. Reproduction in Domestic Animals, 43(3), 273–279.
Virbac Limited. (2016, May 12). Alizin 30 mg/ml solution for injection (GB Only). NOAH Compendium. Retrieved December 7, 2025, from https://www.noahcompendium.co.uk/?id=-459936 .
Smith, S.H., and Goldschmidt, M.H. (2020). Mammary gland. In D. J. Meuten (Ed.), Tumors in Domestic Animals (5th ed., pp. 723–765). Wiley Blackwell.
Zappulli, V., Rasotto, R., Caliari, D., and Castagnaro, M. (2019). Mammary pathology in cats. Veterinary Clinics of North America: Small Animal Practice, 49(1), 209–226.
